Home | Welcome to Contract Pharma   
Last Updated Friday, May 29 2015


Financial Report: Elan 3Q

Published October 25, 2012

3Q Revenues: $306.6 million (+10%)

3Q Loss: $13.7 million (earnings were $670.6 million in 3Q11)*

YTD Revenues: $883.0 million (+11%)

YTD Loss: $30.2 million  (earnings were $755.2 million YTD11)

Comments: Tysabri global in-market sales grew 3% to $403.8 million, reflecting a 17% growth in U.S. sales of Tysabri, offset by an 11% decrease in the rest of world. Loss in the quarter includes charges of $111.3 million related to the separation of the Neotope business and the discontinuation of Elan’s remaining early stage research activities, and an impairment charge of $117.3 million related to the Janssen AI equity method investment following J&J’s discontinuation of bapineuzumab intravenous in Alzheimer’s disease.

*Includes a gain of $664.0 million for the divestment of EDT business.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On